Morgan Stanley Akouos, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.16 $75,176 - $149,196	-28,914 Reduced 48.95%	30,157 $204,000
Q2 2022 Oct 27, 2022	SELL	$2.46 - $5.2 $517,274 - $1.09 Million	-210,274 Reduced 78.07%	59,071 $276,000
Q2 2022 Aug 15, 2022	SELL	$2.46 - $5.2 $517,274 - $1.09 Million	-210,274 Reduced 78.07%	59,071 $276,000
Q1 2022 Oct 27, 2022	BUY	$4.16 - $9.08 $874,739 - $1.91 Million	210,274 Added 355.97%	269,345 $1.28 Million
Q1 2022 May 13, 2022	SELL	$4.16 - $9.08 $141,968 - $309,873	-34,127 Reduced 11.25%	269,345 $1.28 Million
Q4 2021 Feb 14, 2022	BUY	$7.65 - $11.38 $887,193 - $1.32 Million	115,973 Added 61.85%	303,472 $2.58 Million
Q3 2021 Nov 15, 2021	BUY	$9.93 - $13.59 $1.86 Million - $2.55 Million	187,499 New	187,499 $2.18 Million

Ticker AKUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,929,000
Description
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therap...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.